Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles

• Published in: International journal of pharmaceutics Vol. 525; no. 2; pp. 407 - 417
• Main Authors: Labala, Suman, Jose, Anup, Chawla, Sumeet Rajesh, Khan, Mohammed Shareef, Bhatnagar, Shubhmita, Kulkarni, Onkar Prakash, Venuganti, Venkata Vamsi Krishna
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 20.06.2017
• Subjects: Animals; Cell Line, Tumor; Co-delivery; Gold; Gold nanoparticle; Imatinib mesylate; Imatinib Mesylate - administration & dosage; Iontophoresis; Melanoma; Melanoma, Experimental - genetics; Melanoma, Experimental - therapy; Metal Nanoparticles - chemistry; Mice; RNA, Small Interfering - administration & dosage; STAT3 siRNA; STAT3 Transcription Factor - genetics; LbL-AuNP; PVP; MTT; SA; SC; DMEM; Iontophoresis; FITC; PDI; DSC; FBS; FTIR; Co-delivery; Cy3; Gold nanoparticle; PBS; IM; VEGF; STAT3; Melanoma; Imatinib mesylate; DAPI; PKC; siRNA; PAMAM; STAT3 siRNA; CS; RP-HPLC

[Display omitted] Co-delivery of chemotherapeutic agents improve anti-tumor efficacy and reduce cancer resistance. Here, we report development of layer-by-layer assembled gold nanoparticles (LbL-AuNP) containing anti-STAT3 siRNA and imatinib mesylate (IM) to treat melanoma. The combination treatment...